CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced the appointment of Suresh Gunasekaran to its Board of Directors.

Suresh currently serves as President and Chief Executive Officer at UCSF Health, an internationally renowned health system for providing highly specialized and innovative care, including solid organ and bone marrow transplantation. Suresh has more than 20 years of executive leadership experience in healthcare administration and information technology, with a proven track record of driving operational excellence, innovation, and growth at some of the nation’s leading academic medical centers.

“I am excited to join the Board of Directors of CareDx, a genomics company with a deep commitment to improving outcomes for transplant patients and supporting the teams that deliver the care,” said Suresh Gunasekaran. “CareDx’s history of innovation and novel approach to supporting health systems is what attracted me to this opportunity, and I look forward to working closely with the management team to advance diagnostic solutions that will partner with leading health systems to transform care.”

In his role at UCSF, Suresh leads an organization with over $9 billion in annual revenue and 20,000 employees. Prior to UCSF, Suresh was CEO of University of Iowa Hospitals & Clinics and has held senior leadership roles at UT Southwestern Medical Center, Healthlink/IBM, Gartner, and Vanderbilt Children’s Hospital.

“I am thrilled to welcome Suresh to the CareDx Board of Directors,” said John Hanna, President and Chief Executive Officer of CareDx. “Suresh’s voice as a health system leader with a deep commitment to high quality patient care and clinical innovation will be invaluable as we continue to advance our mission of creating life-changing solutions that enable transplant patients to thrive.”

About CareDx

CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit www.caredx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors and other risks discussed in CareDx’s filings with the SEC, including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed by CareDx with the SEC on August 6, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251022703427/en/